Dare Bioscience Q2 net loss narrows as revenue rises, R&D expenses decline

Dare Bioscience

13/08/2026 21:26

Overview
U.S. women's health biotech reported Q2 revenue of $0.2 mln, up from prior year
Net loss for Q2 narrowed compared to same period last year
Company launched Flora Sync LF5, its first directly commercialized product, in July

Outlook
Company began recording revenue from Flora Sync LF5 in July 2026
Company expects to begin recording revenue from DARE to PLAY Sildenafil Cream in Q3 2026
Revenue from DARE to RECLAIM estradiol and progesterone intravaginal ring targeted to begin in 2027

Result Drivers
R&D SERVICES REVENUE - Q2 revenue increase was attributed to research and development services revenues from Gates Foundation agreements, partially offset by lower non-cash royalty revenues
COST OF REVENUES - Cost of revenues in Q2 reflected expenses from performing R&D services and medical education and awareness for commercialization of DARE to PLAY
LOWER R&D EXPENSES - R&D expenses declined mainly due to increased contra R&D expenses and reduced direct costs for Ovaprene Phase 3 and other programs

Company press release: ID:nGNX52Gv9b

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$187,546 
 
Q2 Loss Per Share
 
$0.20
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Dare Bioscience Inc is $9.00, about 525% above its August 12 closing price of $1.44

Reuters Recommended Reads
Aug 11 - TherapeuticsMD Q2 license revenue falls; continues to evaluate strategic alternatives
Aug 13 - Assembly Biosciences Q2 net loss narrows as revenue rises
Aug 13 - Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)